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https://doi.org/10.1016/j.celrep.2021.109929SUMMARYCurrent coronavirus (CoV) vaccines primarily target immunodominant epitopes in the S1 subunit, which are
poorly conserved and susceptible to escape mutations, thus threatening vaccine efficacy. Here, we use
structure-guided protein engineering to remove the S1 subunit from the Middle East respiratory syndrome
(MERS)-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens. Vaccination with MERS SS
elicits cross-reactive b-CoV antibody responses and protects mice against lethal MERS-CoV challenge.
High-throughput screening of antibody-secreting cells from MERS SS-immunized mice led to the discovery
of a panel of cross-reactive monoclonal antibodies. Among them, antibody IgG22 binds with high affinity to
both MERS-CoV and severe acute respiratory syndrome (SARS)-CoV-2 S proteins, and a combination of
electron microscopy and crystal structures localizes the epitope to a conserved coiled-coil region in the
S2 subunit. Passive transfer of IgG22 protects mice against both MERS-CoV and SARS-CoV-2 challenge.
Collectively, these results provide a proof of principle for cross-reactive CoV antibodies and inform the devel-
opment of pan-CoV vaccines and therapeutic antibodies.INTRODUCTION
Coronaviruses (CoVs) are a genetically diverse group of envel-
oped viruses containing a large approximately 30-kb, positive-
sense, single-stranded RNA genome (Li, 2016). Four endemic
(or ‘‘seasonal’’) human CoVs (HCoVs)—HCoV-OC43, -HKU1,
-NL63, and 229E—circulate globally and produce primarily
mild upper respiratory illness in otherwise healthy individuals.
CoVs exhibit adaptation to alternative host species, and spillover
of three novel b-CoVs—Middle East respiratory syndrome
(MERS)-CoV, severe acute respiratory syndrome (SARS)-CoV,
and SARS-CoV-2—from bats directly or indirectly into humans
within the past two decades underscores the serious and persis-
tent threat to public health that CoVs hold. Most recently, SARS-
CoV-2 has led to 200 million cases worldwide and has left in its
wake devastating socioeconomic consequences. Effective vac-
cines not only are crucial for mitigating overall morbidity and
mortality of SARS-CoV-2 infection but also may enable popula-C
This is an open access article under the CC BY-Ntions to achieve herd immunity and temper the emergence and
spread of new viral variants. Many of the coronavirus disease
2019 (COVID-19) vaccines in the global portfolio are based on
an engineered version of the full-length viral attachment protein,
spike (S), stabilized in its prefusion conformation ((Walls et al.,
2020); (Wrapp et al., 2020)). In particular, mRNA-1273 and
BNT162b2 showed >94% efficacy against COVID-19 in adult
phase III clinical trials (Baden et al., 2020; Polack et al., 2020).
However, recent emergence of numerous SARS-CoV-2 variants
harboring diverse changes in S substantiate concerns about the
breadth of this efficacy ((Choi et al., 2020); (Grubaugh et al.,
2021); (Kupferschmidt, 2021); (Tang et al., 2021))
All CoV S proteins are composed of an S1 subunit—a major
determinant for host cell tropism—and an S2 subunit, which
contains the machinery that drives virus-cell fusion (Li, 2016;
(Siebert et al., 2003)). The S1 subunit, which directly interacts
with the host receptor, is composed of an N-terminal domain




OPEN ACCESS(SDs). For SARS-CoV-2, transient hinging of the RBD into an
‘‘up’’ conformation allows for host-cell receptor engagement.
In the S2 subunit, a helix-loop region spanning from the fusion
peptide (FP) to heptad repeat 1 (HR1) constitutes a metastable
structure that transitions to a long stable a-helix in the postfusion
conformation during viral entry. The FP, HR1, central helix (CH),
and connector domain (CD) compose the globular head of the S2
subunit. In contrast, the helical stalk region connecting the glob-
ular head to the viral membrane is elongated and highly flexible
((Ke et al., 2020); (Turonová et al., 2020)). The stalk region can
be further divided into a hip, knee, and ankle, in which the
knee functions as a hinge, providing a considerable degree of
flexibility and promoting movement of S on the viral surface.
As the S1 is responsible for interacting directly with the host re-
ceptor, the majority of vaccine-induced antibodies and anti-
bodies elicited upon natural infection target this subunit, which
contains the immunodominant RBD (Corbett et al., 2020b,
2020a; (Jackson et al., 2020)). In addition, a portion of neutral-
izing monoclonal antibodies (mAbs) isolated from convalescent
COVID-19 patients recognize the NTD ((Chi et al., 2020); (Liu
et al., 2020)). Amino acid changes are concentrated in the S1
subunit among the majority of SARS-CoV-2 variants described
thus far. Additionally, recent data suggest that antibodies in
convalescent sera that target neutralization-sensitive epitopes
in the S1 domain create a selective pressure that yields escape
mutations in these epitopes ((Andreano et al., 2021)).
Several new SARS-CoV-2 ‘‘variants of concern (VOC),’’ distin-
guished by one to many unique or recurring changes in S,
recently emerged. These variants have spread at disproportion-
ately fast rates relative to predecessor variants in certain
geographic regions, consistent with an augmented replication
capacity, greater transmissibility, and/or immune evasion.
Among recurring changes, multiple amino acid deletions in the
NTD (del 69-70, del 144, and del 242-244) and K417N/T,
E484K, and N501Y substitutions in the RBD have garnered spe-
cial attention due to an enhanced affinity of S for the SARS-
CoV-2 receptor angiotensin converting enzyme 2 (ACE2) and
reduced sensitivity to neutralization by convalescent polyclonal
sera and anti-RBD therapeutic mAbs ((Gu et al., 2020); (Starr
et al., 2020); (Wang et al., 2021); (Weisblum et al., 2020); (Wu
et al., 2021); (Zhao et al., 2021)). The del 69-70 and N501Y alter-
ations have evolved both together and separately in independent
VOC lineages, as has the E484K mutation ((Ku et al., 2021)).
Altogether, these data indicate that selective pressures on the
neutralization-sensitive epitopes of the S1 subunit ultimately
result in escape variants.
Although most neutralizing antibodies target the S1 subunit,
the S2 subunit is more conserved, likely constrained by the com-
plex and precisely timed refolding events essential for produc-
tive viral entry. Nevertheless, antibodies targeting this region
may be neutralizing and protective against infection and pathol-
ogy in vivo ((Chi et al., 2020); (Ng et al., 2020); (Zhang et al.,
2021)). Notably, it has been observed that SARS-CoV-2-infected
children and young adolescents recently infected with an
endemic HCoV develop higher titers of S2 antibodies than
SARS-CoV-2-infected adults without a recognized antecedent
endemic HCoV infection (Ng et al., 2020). Memory B cells trained
on conserved S2 epitopes and stimulated by SARS-CoV-2 infec-2 Cell Reports 37, 109929, November 2, 2021tion may account for the skewed neutralizing antibody response
to the SARS-CoV-2 S2 subunit in young individuals. In individ-
uals not previously infected with SARS-CoV-2, a majority of
the anti-SARS-CoV-2 immunoglobulin G (IgG) repertoire targets
the S2 subunit, underscoring the potential for cross-reactivity
directed at conserved epitopes on HCoVs ((Nguyen-Contant
et al., 2020)). Thus, the S2 subunit serves as an attractive target
for the development of broad-spectrum vaccines and therapeu-
tic antibodies for current and future novel HCoVs.
In this report, we describe the design and study of two MERS-
CoV stabilized stem (SS) constructs, namely, MERS SS.V1 and
MERS SS.V2, both of which lack the S1 subunit (Figure 1A).
We show that both antigens are highly immunogenic in mice,
inducing broadly cross-reactive antibodies to MERS-CoV,
HCoV-HKU1, SARS-CoV, and SARS-CoV-2 S, and confer pro-
tection in a lethal murine MERS-CoV challenge model. Two
mAbs, namely, IgG22 and IgG72, isolated using microfluidic sin-
gle B cell screening technology from MERS SS.V1-immunized
mice, neutralized authentic MERS-CoV. Strikingly, the passive
transfer of IgG22 protected mice from both MERS-CoV and
SARS-CoV-2 lethal challenge. Single-particle cryoelectron mi-
croscopy (cryo-EM) studies revealed that IgG22 binds a region
in the S2 stalk of MERS-CoV and SARS-CoV-2 S proteins that
undergoes substantial changes during the pre-to-postfusion
conformational transition. High-resolution crystal structures of
the stalk peptide–antibody complexes further provided a basis
for binding of this stalk-targeting antibody to highly conserved
sequences in human b-CoVs. Our findings establish the feasi-
bility of rationally designing stabilized S2 constructs as protec-
tive vaccine immunogens against emerging HCoVs, which
upon further development may exhibit efficacy against divergent
HCoV species. In addition, stem cross-reactive antibodies may
serve as valuable tools for prospective serological surveillance
of future CoV spillover into humans.
RESULTS
Structure-based vaccine design of MERS-CoV SS
antigens
To stabilize the stem region (S2 subunit) of S, we first used the
Protein Repair One-Stop Shop (PROSS) algorithm to computa-
tionally design stabilizing mutations based on a prefusion-stabi-
lized structure of the MERS-CoV S ectodomain (PDB: 5W9I)
(Goldenzweig et al., 2016; Pallesen et al., 2017). Among 53 de-
signs, 11 substitutions were selected and introduced in various
combinations into the S2 subunit of MERS-CoV S. The protein
expression level of the mutant containing all 11 substitutions
(mut11) was substantially higher than that of MERS S2-2P
(base construct) (Figure 1B). To further improve the protein
expression and thermostability of S2, we used a variety of stabi-
lization strategies to design 12 different substitutions, which
were added onto the mut11 background. The strategies we
used include using hydrophobic residues to fill loosely packed
internal cavities such as S975M substitution (Figures 1A and
1C), disulfide bonds to lock the regions that move substantially
during the pre-to-postfusion transition such as T803C/K933C
substitution (Figures 1A and 1D), polar residues to counter inter-
nal charge imbalance such as V958S substitution (Figures 1A
Figure 1. Characterization of MERS stem stabilized (SS) spike (S) variants
(A) Side view of the trimeric MERS-CoV globular S ectodomain in a prefusion conformation (PDB: 5W9I) with S1 subunits omitted. One protomer of the S2 subunit
is shown as a ribbon diagram with the other two protomers shown in a transparent molecular surface. The regions that refold during the pre-to-post-fusion
transition are colored cyan with the rest of S2 in tan. Each inset corresponds to the location of beneficial substitutions in the MERS SS.V1 construct.
(B) SDS-PAGE of MERS-CoV S2-2P and individual S variants on mut11 backbone. Molecular weight standards in kDa are indicated at the left.
(C–E) Size-exclusion chromatography (SEC) traces of purified S variants, grouped by type (C, cavity and aromatic; D, disulfide; E, polar and salt bridge). A vertical
dotted line indicates the peak retention volume for S2-2P.
(F) SEC traces for combinatorial disulfide-substituted S variants. One or two additional disulfide substitutions are introduced on the MERS SS.V1 backbone.
See Figures S1 and S2.
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actions with positively charged residues such as L923W/L1033F
substitution (Figures 1C and S1A). Except for the S858C/G953C
variant, all other single substitutions increased the protein
expression to various extents compared with mut11. Particu-
larly, S975M, L923W/L1033F, Q769C/S858C, T803C/K933C,
S845E, A1049S, and A1093R substitutions exhibited a more
than 10-fold higher expression compared to their parental
construct mut11 (Figures 1B–1E). The size-exclusion chroma-
tography (SEC) traces of all variants showed a major trimeric
peak with some minor shoulder peaks, with the retention vol-
umes of the trimeric variants being similar to the base construct
and mut11.
Next, we sought to examine the contribution of the individual
substitutions comprising mut11 to protein expression and ther-mostability by reverting each of the substitutions back to the
wild-type (WT) residue. Reverting K816R, H1020Q, H1146Y,
or V1150T increased the protein expression relative to mut11,
meaning these four substitutions in mut11 are dispensable.
Thus, a new base construct containing 7 substitutions (mut7)
was used for subsequent designs (Figure S1B). To test whether
our structure-based designs (previously tested individually on
the mut11 background) have additive effects, we added a di-
sulfide design (T803C/K933C), a cavity filling design (S975M),
or a combination of both designs (S975M, T803C/K933C) on
top of mut7. However, unlike the increase in expression for
mut11, T803C/K933C decreased the protein expression rela-
tive to mut7 but increased the melting temperature (Tm) by
1.7C (Figure S1C). S975M substitution not only boosted pro-
tein expression relative to mut7, but also enhanced theCell Reports 37, 109929, November 2, 2021 3
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the mut7 backbone restored the expression to a level similar
to mut7 and increased Tm by 4.0C. After iterative screening
of WT reversions in mut7 S975M/T803C/K933C, we found
that A918P and V1139F had adverse effects on protein expres-
sion and thermostability (Figures S1D and S1E). Removal of
A918P and V1193F resulted in our first SS antigen, MERS
SS.V1 (Figures S1B and S1C), containing 7 substitutions in
addition to the original 2P substitutions (S975M, T803C/
K933C, V958S, V983I, S1091E, L1094Q, N1132Y, V1060P,
and L1061P).
To evaluate the viability of MERS SS.V1 as an immunogen, we
investigated large-scale production in FreeStyle 293-F cells,
thermostability, and epitope integrity. After two consecutive
runs of SEC, MERS SS.V1 exhibited a monodispersed trimeric
peak, with a yield of 2.2 mg from 1 L of cell culture. The Tm of
MERS SS.V1 is 59.9C, which is a 6.3C increase relative to
mut11 (Figure S1F and S1G). mAb G4 is one of very few S2-
directed antibodies showing neutralizing activity to MERS-CoV
(Wang et al., 2015). The binding kinetics of MERS SS.V1 to G4
IgG were comparable to those of the MERS S-2P ectodomain,
with apparent affinities of 8.5 nM and 13.2 nM, respectively (Fig-
ures S2A and S2B). We also examined the conformation of
MERS SS.V1 complexed with G4 Fab by negative stain electron
microscopy (nsEM) analysis (Figure S2C). Although the images
from 2D class averages of SS.V1 did not resemble an elongated
postfusion conformation, it was not clear that our SS antigens
maintained a fully prefusion state. Taken together, these results
suggest that MERS SS.V1 retains the integrity of the known
neutralization epitope and should be amenable to large-scale
production.
Introducing disulfide linkages to lock viral glycoproteins in
the prefusion conformation has proven effective in class I viral
fusion proteins such as respiratory syncytial virus (RSV) F, hu-
man immunodeficiency virus type 1 (HIV-1) Env, and Ebola GP
((McLellan et al., 2013); (Rutten et al., 2020); (Sanders et al.,
2013)). Although it was not successfully applied to the S2 sub-
unit of the SARS-CoV-2 S (Hsieh et al., 2020), it was effective to
lock the RBD from the S1 subunit to the S2 subunit and stabi-
lize a closed S trimer conformation (Henderson et al., 2020;
McCallum et al., 2020; Xiong et al., 2020). We thus explored
the feasibility of the disulfide design on MERS SS.V1. Three di-
sulfide designs, namely, A838C/S1089C, S845C/A1096C, and
V898C/V1022C, were introduced individually or in combination
to stabilize the region proximal to the FP and CH. With the
addition of V898C/V1022C, the protein expression level
increased 1.3-fold relative to MERS SS.V1 and the Tm
increased by 4.0C (Figures 1F and S1F). Upon combination
with either A838C/S1089C or S845C/A1096C substitutions,
the protein expression levels increased 1.7-fold relative to
MERS SS.V1 and the Tm increased by 6.3C. Notably, both
constructs exhibited a sharp monodisperse trimeric peak on
SEC without any prominent shoulder peaks. This led to our
best construct, namely, MERS SS.V2, which contains A838C/
S1089C and V898C/V1022C added onto the MERS SS.V1
background. The large-scale expression of MERS SS.V2 out-
performed MERS SS.V1, yielding 9.5 mg from 1 L of FreeStyle
293-F cells (Figure S1G).4 Cell Reports 37, 109929, November 2, 2021MERS SS immunization elicits cross-reactive b-CoV
antibodies
To evaluate the cross-reactive immunogenicity of MERS SS im-
munogens, we immunized BALB/cJ mice with 0.4, 2, or 10 mg of
MERS SS.V1 or SS.V2 or the maximally effective dose of 1 mg of
stabilized MERS S ectodomain (MERS S-2P) (Pallesen et al.,
2017; Figure 2A). All doses of both immunogens elicited 105
MERS S-2P-specific reciprocal endpoint binding titers at
2 weeks post-boost (Figure 2B). Both MERS SS.V1 and SS.V2
elicited HCoV-HKU1, SARS-CoV, and SARS-CoV-2 S-2P-spe-
cific IgG that trended toward dose dependency; most notably
at the 0.4 mg dose, heterotypic SARS- and SARS-2 S-2P-spe-
cific binding IgG responses were more significant in mice immu-
nized with SS.V1 than in mice immunized with SS.V2 (Figures
2C–2E). Conversely, neutralizing antibody responses against a
pseudotyped lentivirus reporter expressing MERS-CoV S were
not dose dependent. As expected, both SS immunogens elicited
significantly fewer neutralizing antibodies thanMERS S-2P given
the lack of the S1 subunit in the SS immunogens. Although
MERS SS.V1 elicited only modest baseline neutralizing antibody
responses (up to a geometric mean reciprocal ID50 titer, geomet-
ric mean titer [GMT] = 156), SS.V2 induced stronger neutraliza-
tion responses with a GMT of 550 ID50 (Figure 2F). Altogether,
these data corroborate that the introduction of stabilizing
disulfide bonds into the SS.V1 backbone promotes the produc-
tion of more potently neutralizing MERS-CoV S2-specific anti-
bodies. Additionally, they underscore the importance of target-
ing conserved epitopes to induce broad binding antibody
responses.
MERS SS protects humanized-DPP4 mice against lethal
MERS-CoV challenge
In order to assess the ability of MERS SS immunogens to protect
against lethal MERS-CoV challenge, we immunized 288/330+/+
mice (Corbett et al., 2020a)with10mgofMERSSS.V1orS-2P, ad-
juvanted with Sigma Adjuvant System (SAS) at weeks 0, 3, and
9—inclusive of an additional boost to further promote cross-reac-
tive humoral responses. Mock-immunized mice received PBS
(Figure 3A). In 288/330+/+mice, theDpp4 gene has beenmodified
to encode two amino acids on positions 288 and 330 tomatch the
human gene, rendering them susceptible to MERS-CoV infection
and replication. Serial passaging led to amouse-adapted version
of MERS-CoV (maM35c4) ((Douglas et al., 2018)) that not only
replicated efficiently in mouse lungs but also caused symptoms
like weight loss, decreased pulmonary function, and histopatho-
logical manifestations of severe lung disease (Figure 3A). First,
ELISA revealedMERS SS.V1 elicits similar levels (105) of homo-
typic binding IgG as MERS S-2P (Figure 3B). However, stem-
specific binding antibodies were sub-neutralizing as MERS
SS.V1-immunized mice had significantly reduced homotypic
pseudovirus neutralizing antibody responses (geometric mean
reciprocal ID50 titer, GMT = 185) as compared to mice receiving
MERS S-2P (GMT = 5,758), similar to BALB/cJ mice in Figure 2F.
In fact, only 5 out of 20MERS SS.V1-immunized 288/330+/+ mice
had detectable neutralizing antibody responses (Figure 3C).
Following challenge, 4 weeks post-boost, mice immunized
with either MERS S-2P or MERS SS.V1 demonstrated no weight
loss throughout the course of infection. Conversely, mice in the
Figure 2. Immunogenicity of MERS SS immunogens in mice
(A) BALB/cJ mice (N = 10/group) were inoculated with PBS (gray); 1 mg of MERS S-2P (red); or 0.4, 2, or 10 mg of MERS SS.V1 (blue) or SS.V2 (green) adjuvanted
with Sigma Adjuvant System (SAS). Mice were immunized at weeks 0 and 3 and bled at week 5 (2 weeks post-boost) for serological assessments.
(B–E) ELISAs to quantify S-2P specific binding IgG titers for MERS-CoV (B), HCoV-HKU1 (C), SARS-CoV (D), and SARS-CoV-2 (E). Red line respresents the GMT
of MERS S-2P immunized group.
(F) Neutralizing antibody titers against MERS-CoV England1 pseudovirus. The dotted line represents the lower limit of detection.
In (B) to (F), each circle represents and individual mouse. Box and whisker plots are shown. Boxes and horizontal bars denote the interquartile range (IQR) and
medians, respectively; whisker end points are equal to the maximum and minimum values. In (B) to (E), two-way ANOVA with multiple comparisons post-tests
were used to compare doses within immunogen group and groups at each dose. In (F), groupswere compared by one-way ANOVAwith Kruskal-Wallis post-test .
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
See Figures S3 and S4.
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and succumbed to weight loss by 1 week post-challenge (Fig-
ure 3D). At day 3 post-challenge, the day of peak lung viral titersin this model, MERS S-2P-immunized mice had no detectable
lung viral load, and lung viral titers in MERS SS.V1-immunized
mice hovered about the viral detection limit (geometric meanCell Reports 37, 109929, November 2, 2021 5
Figure 3. Efficacy of SS.V1 against lethal MERS-CoV challenge in mice
(A) 288/330+/+ mice (N = 20/group) were immunized at weeks 0, 3, and 9 with PBS (gray) or 10 mg of MERS-CoV S-2P (red) or SS.V1 (blue) adjuvanted with SAS.
(B–C) At week 11 (two weeks post-boost 2), mice were bled for analysis of MERS-CoV S-2P-specific IgG (B) and MERS-CoV maM35c4 pseudovirus neutralizing
antibodies (C).
(D) Following challenge, mice were monitored for weight loss. The mean of each group is represented by a circle, error bars represent SEM.
(E–H) At days 3 and 5 post-challenge, a subset of mouse lungs (n = 5/time point) was harvested for analysis of viral titers (E and F) and tissue discoloration (G and
H) (0 = no discoloration, 4 = severe discoloration in all lobes). (B, C, and E–H) Each circle represents an individual mouse. Box and whisker plots are shown. Boxes
and horizontal bars denote the interquartile range (IQR) and medians, respectively; whisker end points are equal to the maximum and minimum values. Dotted
lines represent lower limit of detection.
In (B) to (C) and (E) to (H)experimental groups were compared to the PBS control group by one-way ANOVA with Kruskal-Wallis post-test. In (D), experimental
groups were compared to the PBS control group at each day post challenge by one-way ANOVA with Kruskal-Wallis post test. Statistics account for varability in
mouse numbers following lung harvest. ND indicates statistical analysis is not determined due to limited number of PBS control mice. *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001.
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OPEN ACCESSPFU per lung lobe = 167) (Figure 3E). By day 5 post-challenge,
MERS SS.V1- and S-2P-immunized mice alike had cleared viral
replication, contrasting against PBS-immunized mice, which
had 2 3 106 geometric mean PFU per lung lobe (Figure 3F). In
line with trends of viral replication among SS.V1- and S-2P-6 Cell Reports 37, 109929, November 2, 2021immunized mice, at both days 3 and 5 post-challenge, there
was little to no distinguishable pulmonary damage, as evidenced
by low discoloration scores, indicating that both vaccines effec-
tively protected against lung viral replication and disease (Fig-
ures 3G and 3H). These findings emphasize the utility of eliciting
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OPEN ACCESSprotective immunity by targeting epitopes outside immunodomi-
nant and neutralization-sensitive S1 sites.
Discovery of pan-CoV antibodies from MERS SS-
immunized mice
Next, we used AbCellera’s single B cell technology to isolate
cross-reactive mAbs from the spleen, thymus, and lymph no-
des of mice immunized with the MERS SS.V1 antigen. Using
HCoV-HKU1 S-2P, SARS-CoV S-2P, MERS-CoV S-2P, and
MERS SS.V1 as probes, we discovered 146 antibodies with a
diverse spectrum of specificities to the b-CoV S proteins. We
selected for antibodies exhibiting broader S reactivities, higher
frequencies, and unique CDR3s in both heavy and light chains
in order to cover a wide distribution of the germline family. The
selected IgGs were then expressed recombinantly in vitro and
characterized by binding specificities to b-CoV prefusion-sta-
bilized S, namely, HCoV-HKU1 S-2P, MERS-CoV S-2P, and
SARS-CoV S-2P. IgG20, IgG23, and IgG62 demonstrated
cross-reactive binding to MERS- and SARS-CoV S with higher
apparent affinity to the former (Figure S3A). Intriguingly, IgG21,
IgG22, and IgG72 were also MERS and SARS-specific, but the
association rates of these mAbs to SARS-CoV S were nearly
5-fold higher than those to MERS-CoV S (Figure S3B). In
contrast, IgG12, IgG19, and IgG42 only bound to MERS-CoV
S (Figure S3C). We also performed competitive binding exper-
iments with G4, the only MERS S2-targeted antibody with a
structurally defined epitope (Pallesen et al., 2017). One-third
of selected mAbs (IgG20, IgG23, and IgG62) competed with
G4 binding to MERS-CoV S (Figures S4A and S4B). By
contrast, IgG12, IgG19, IgG21, IgG22, IgG42, and IgG72 ap-
peared to bind to regions outside the G4 epitope. Although
the initial screening from single B cell technology showed
that IgG7 reacted with HKU1 S-2P, IgG7 was shown to target
a foldon trimerization motif that was artificially linked to all of
the S antigens and the control RSV F protein. Finally, we per-
formed a nsEM analysis for one of the non-G4 competing anti-
bodies, Fab20, complexed with MERS-CoV S. In line with
competitive binding data, the low-resolution reconstruction of
the complex indicated that Fab20 bound to a different site
from the G4-binding loop at the bottom of the S2 subunit
(Figure S4C).
IgG22 binds to multiple CoV S proteins and neutralizes
authentic MERS-CoV
IgG22 and the clonally related IgG72 are two of the cross-reac-
tive antibodies that exhibited faster association to SARS-CoV S
than MERS-CoV S (Figure S3B). To determine the kinetics of
their interactions, we performed surface plasmon resonance ex-
periments for which we flowed Fab over S ectodomain immobi-
lized to a sensor chip. The binding affinity of Fab22 toMERS-CoV
S was comparable to those of SARS-CoV S and SARS-CoV-2 S,
with equilibrium dissociation constant (KD) values of 2.9 nM,
7.2 nM, and 6.7 nM, respectively (Figures 4A–4C). However,
Fab22 exhibited distinct binding kinetics to MERS-CoV S,
featuring a much slower on-rate and off-rate than SARS-CoV
or SARS-CoV-2 S. We examined the neutralization activities of
selected mAbs against authentic MERS-CoV. IgG22 and IgG72
exhibited potent neutralizing activity, with IC50 values of0.12 mg/ml and 2.45 mg/ml, respectively (Figure 4D). On the other
hand, IgG20, IgG21, and IgG42 showed no neutralization activity
against MERS-CoV. Interestingly, IgG22 and IgG72 failed to
neutralize authentic SARS-CoV-2 (Figure 4E), which may be
due to the faster off-rate of IgG22 from SARS-CoV-2. However,
we cannot rule out other possibilities, such as differences in S
density between the two viruses.
Cryo-EM structure of Fab22 bound to the MERS-CoV S
To investigate Fab22 and Fab72 binding sites on S, we per-
formed nsEM analysis for the Fab-S complexes. 2D classifica-
tion showed three distinct densities for Fab22 attached to the
S2 stalk region of MERS-CoV S-2P, a region that undergoes
substantial conformation changes during the pre-to-postfusion
transition (Figure S5A). Interestingly, Fab72 also binds to a
similar region of S2 in proximity to HR2 (Figure S5B). Given
that the binding of HR2 could potentially prevent virus-cell
membrane fusion, we sought to determine a cryo-EM structure
of Fab22 bound to MERS S-2P. Similar to the nsEM analysis
results, we were able to see three distinct Fab densities from
multiple 2D classes (Figure 4F). The initial 3D reconstruction ex-
hibited a single conformation of the S, with all three RBDs in the
down conformation. A total of 183,556 particles led to a 3.3-Å
reconstruction with well-defined side chains densities at the
core of S2. Three Fab volumes could be visualized at the bot-
tom stalk of S2, although one of the Fabs displayed a broader
than usual Fab volume. It is possible that the highly flexible na-
ture of the stalk-HR2 region could lead to broadened Fab vol-
umes. Therefore, the initial set of particles was subjected to
two additional rounds of heterogeneous refinement to sort out
3D classes with diverse Fab orientations. We were able to
obtain a 3D reconstruction (3.3 Å) from about one-half of the to-
tal particles (48.7%) demonstrating three distinct Fabs bound to
the S. Interestingly, both reconstructions displayed three-RBD-
down conformations. Focused refinement on the Fab22 vol-
umes was attempted, but the Fab-S interface could not be
resolved.
Cryo-EM structure of Fab22 bound to the SARS-CoV-2 S
Similar to the Fab22-MERS-CoV S complex, nsEM analysis
showed that Fab22 binds to the stalk region of SARS-CoV-2 S
(Figure S5C). To ascertain the discrepancy between the
MERS-CoV and SARS-CoV-2 neutralization by IgG22, we at-
tempted to determine a high-resolution structure of Fab22
bound to SARS-CoV-2 S HexaPro, a prefusion-stabilized S
(Hsieh et al., 2020). The initial 3D reconstruction exhibited a
disc-shaped Fab volume beneath the helical stalk of the glob-
ular ectodomain. After two additional rounds of heterogeneous
refinement, we were able to sort out two different conformations
of S, as follows: one-RBD-up at 4.0 Å (53% of the total particles)
and three-RBD-down at 4.4 Å (31% of the total particles) (Fig-
ures 5A and 5B). Although Fab22 volumes were not well defined,
the Fab binding site on the S could be located to the helical
stalk, which is only resolved in the full-length S model (PDB:
6XR8) (Figure 5C). Sequence alignments of the helical stalk
show that, among the b-CoVs, HCoV-HKU1 is the least
conserved in this region. This finding could explain why IgG22
has nearly no affinity to the HCoV-HKU1 S. To further narrowCell Reports 37, 109929, November 2, 2021 7
Figure 4. MERS stem-targeted mAbs neutralize authentic MERS-CoV
(A–C) Binding of Fab22 to MERS-CoV S (A), SARS-CoV S (B), and SARS-CoV-2 S (C) assessed by surface plasmon resonance. Binding data are shown as black
lines, and the best fit to a 1:1 binding model is shown as red lines.
(D) IgG22 and IgG72 demonstrated concentration-dependent neutralization of MERS-CoV infectivity. Other SS.V1 elicited mAbs shown lacked detectable
neutralizing activity against MERS-CoV. mAbs IgG20, IgG22, and IgG72 were tested in duplicate, and remaining mAbs were tested once. Neutralizing mAb G4
was included as a positive control and tested in triplicate.
(E) Neither IgG22 nor IgG72 exhibited detectable neutralization of SARS-CoV-2. mAb S309, which neutralizes SARS-CoV-2, was included as a positive control.
IgG22 and IgG72 were tested once, and S309 was tested in duplicate.
(F) Representative 2D class averages and cryo-EMmap of Fab22 bound toMERS S-2P. Themap is colored by local resolution. The side view and top-down view
of the Gaussian filtered maps indicate distinct Fab volumes.
See Figure S5 and Table S1.
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OPEN ACCESSdown the binding site, we constructed the following two C-ter-
minal truncations of the S variants: DHR2 (1–1160) and Dstalk
(1–1142). In line with the cryo-EM map, Fab22 retained affinity
to HexaPro-DHR2 but completely lost binding to HexaPro-D
stalk (Figure 5D). Collectively, these data demonstrate that the
conserved helical stalk region between residues 1142 and
1160 is an epitope with the potential to elicit cross-reactive
S2-targeted antibodies.
Crystal structures of Fab22 in complex with MERS-CoV
S and SARS-CoV-2 S stem helix peptides
To gain molecular insight into the ability of Fab22 to bind both
MERS-CoV S and SARS-CoV-2 S, we determined crystal struc-
tures of Fab22 bound to either a MERS-CoV S peptide or a
SARS-CoV-2 S peptide containing the putative S2 epitope
(Sauer et al., 2021; Figures 6A, 6B, and S6). These structures re-
vealed that Fab22 can bind both MERS-CoV and SARS-CoV-2 S
by engaging residues that are conserved between both viruses.
The Fab22–peptide interfaces each contain 3 key hydrophobic
interactions, formed by Leu1235, Phe1238, and Phe1239 in8 Cell Reports 37, 109929, November 2, 2021MERS-CoV S and by Leu1152, Tyr1155, and Phe1156 in
SARS-CoV-2. These conserved residues occupy the same posi-
tion in both structures, with Phe1239/Phe1156 sandwiched be-
tween CDRH3 Arg100c and CDRH1 Phe33, and with Leu1235/
Leu1152 and Phe1238/Tyr1155 packing into identical hydropho-
bic pockets of Fab22 (Figures 6C and 6D). In addition, the
conserved Asp1236/Asp1152 forms a salt bridge with CDRH3
Arg100c, and the conserved Glu1234/Glu1151 forms a salt
bridge with CDRH2 Lys58 (Figures 6C and 6D). The conservation
of these five positions in the Fab22 epitope provides a molecular
basis for its cross-reactivity (Figure 6E).
IgG22 protects mice against lethal MERS-CoV and
SARS-CoV-2 challenge
The observed cross-reactivity of IgG22 to MERS-CoV and
SARS-CoV-2 S suggested its ability to protect against both vi-
ruses in vivo. We first assessed protection against a lethal
dose of MERS-CoV using mouse-adapted strain maM35c4
((Douglas et al., 2018)) in 288/330+/+ mice ((Corbett et al.,
2020b); Figure S7A), and subsequently, for SARS-CoV-2, we
Figure 5. Stem-targeted IgG22 binds to heli-
cal stalk region of SARS-CoV-2 S
(A) Representative 2D class averages and 3D re-
constructions of Fab22 bound to SARS-CoV-2 S.
(B) Side view of the cryo-EM map of Fab22 bound
to SARS-CoV-2 S. The map is colored by local
resolution. Fab22 binds to the base of the S.
(C) Model of full-length wild-type SARS-CoV-2 S
(PDB: 6XR8) docked into EM map of Fab22 bound
to SARS-CoV-2 S. The S protein is colored green,
and the helical stalk is colored blue. Zoomed view
of the helical stalk has side chains shown in blue
and N-linked glycans shown in pink.
(D) Binding of Fab22 to three SARS-CoV-2 S vari-
ants captured by RBD-directed IgG S309 is as-
sessed by biolayer interferometry (BLI). Binding
data are shown as black lines, and the best fit to a
1:1 binding model is shown as red lines.
See Figure S5 and Table S1.
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OPEN ACCESSused a BALB/c model (Dinnon et al., 2020; Leist et al., 2020; Fig-
ure 7A). In both models, 2 or 20 mg/kg of IgG22 or 20 mg/kg of
MERS-CoV S2-directed mAb G4 ((Wang et al., 2018)) was
passively transferred into mice and compared to mock-immu-
nized, PBS control mice (Figures S7A and 7A). IgG22 protected
against homotypic MERS-CoV challenge in a dose-dependent
fashion; 20 mg/kg of IgG22 and G4 significantly reduced weight
loss as compared to PBS control mice, which demonstrated an
average loss of 14.1% of the initial starting weight by day 5 post-
challenge (Figure S7B). In contrast, there was no difference
comparing PBS control mice and mice immunized with 2 mg/
kg of IgG22 (Figure S7B). These results were mirrored in assess-
ments of lower airway viral replication and disease. On day 5
post-challenge, PBS control mice had a geometric mean of
5.0 3 104 PFU/lobe and the 2- and 20-mg/kg IgG22 group had
70.5-fold and 6.7-fold less lung-resident MERS-CoV, respec-
tively (Figure S7D). Additionally, discoloration of lung tissues
was completely inhibited in both the 20-mg/kg IgG22 and G4
groups, but evidence of lung discoloration was present in the
2-mg/kg IgG22-immunized and PBS-control mice by the fifth
day post-challenge (Figure S7C). In the upper airway, by day 5,
there was significantly less (8.7-fold) MERS-CoV in nasal turbi-
nates of mice that received 20 mg/kg IgG22 as compared to
PBS control mice; however 2-mg/kg IgG22 did not prevent up-
per airway MERS-CoV replication (Figure S7E). Notably, across
all measurements, there were similarities in the ability of mAbs
G4 and IgG22 to protect against MERS-CoV-2, further suggest-
ing these two S2-directed potently neutralizing antibodies pro-
vide homotypic protection by a similar mechanism.
For SARS-CoV-2 challenge, mice were infected with 104 PFU
SARS-CoV-2MA10 (Leist et al., 2020) at 24 hours following intra-Ceperitoneal (i.p.) treatments. Mice immu-
nized with 20 mg/kg of mAb G4, 2 mg/kg
of IgG22, and PBS all demonstrated
similar trends in weight loss kinetics—
losing on average 17.3%, 14.6%, or
19.0% of the initial starting weight,
respectively—by day 4 post-challenge(Figure 7B). In contrast, mice in the 20-mg/kg IgG22 group main-
tained their weight throughout the challenge, only losing 1% of
the starting bodyweight on average by day 4 post-challenge (Fig-
ure 7B). On day 4 post-challenge, mice that received 20-mg/kg
IgG22 showed significantly lower (10.5-fold) lung SARS-CoV-2
than the PBS control mice. In a dose-dependent fashion, there
was a modest 1.7-fold lower SARS-CoV-2 titer in lungs of mice
immunized with 2-mg/kg IgG22 than in PBS control mice (Fig-
ure 7D). There were negligible differences in nasal turbinate
SARS-CoV-2 titers across all groups, suggesting that IgG22, at
up to 20 mg/kg, was insufficient at preventing viral replication in
the upper airway (Figure 7E). In all, the ability of IgG22 to prophy-
lactically protect against both homotypicMERS-CoV and hetero-
typic SARS-CoV-2 in mice shows promise for the use of SS anti-
gens, such as MERS SS, to induce not only cross-reactive but
also protective antibody responses against related HCoVs. The
efficacy of IgG22 in heterotypic challenge additionally empha-
sizes the utility of such cross-reactive S2-directed antibodies in
acute prevention of CoV lower airway disease.
DISCUSSION
The S2 subunit of CoV S, analogous to HA2 of influenza virus
hemagglutinin (HA) and gp41 of HIV-1 Env, functions as a fus-
ogen by bringing viral and host cell membranes together, thus
enabling viral entry. To mediate fusion, the S2 subunit transi-
tions from a metastable prefusion to a highly stable post-fusion
conformation (Li, 2016). We previously reported that the intro-
duction of stabilizing mutations into the S2 subunit of MERS-
CoV, SARS-CoV, and SARS-CoV-2 permitted the production
of large quantities of prefusion-stabilized trimeric full-length Sll Reports 37, 109929, November 2, 2021 9
Figure 6. IgG22 binds to a conserved region
in S2
(A and B) Crystal structure of Fab22 bound to the
MERS-CoV (A) and SARS-CoV-2 (B) stem helix
peptides. Heavy and light chains of the Fab are
shown as molecular surfaces, and the main chain
of the peptides is shown as a tube, with the side
chains shown as sticks. Oxygen atoms are colored
red and nitrogen atoms are colored blue. The
N-terminal and C-terminal residues of the peptides
are labeled.
(C and D) Zoomed-in view of the interface between
Fab22 and the MERS-CoV (C) and SARS-CoV-2
(D) stem helix peptides. Fab22 is shown as a rib-
bon, and the main chain of the peptides is shown
as a tube, with the side chains shown as sticks.
(E) Alignment of the stem helix region of S proteins
from multiple b-CoVs. Fab22 interface residues
conserved between MERS-CoV and SARS-CoV-2
are denoted with a red dot.
See Figure S6 and Table S2.
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OPEN ACCESSretaining well-folded 3D structures resembling native S on the
virion surface (Hsieh et al., 2020; (Ke et al., 2020); (Kirchdoerfer
et al., 2018); Pallesen et al., 2017; (Turonová et al., 2020);
(Wrapp et al., 2020)). Importantly, neutralization-sensitive epi-
topes and host-receptor-binding sites in the S1 subunit were
completely preserved. Collectively, the strategy of stabilizing
S through engineered prevention of S2 refolding has been
successful for generating vaccine antigens that protect animals
in CoV-challenge models and humans from SARS-CoV-2 infec-
tion (Baden et al., 2020; Corbett et al., 2020a, 2020b; Polack
et al., 2020).
Efforts toward a universal influenza A virus (IAV) vaccine yielded
the first proof of concept for exploiting antigenic conservation in
the HA stem region (functionally analogous to the CoV S2 subunit)
to elicit broadprotection in animals. Specifically, two independent
research groups rationally engineered theHA stemby introducing
disulfide bridges, increasing surface hydrophilicity, stabilizing the
hydrophobic core, optimizing the protease cleavage site, and/or
displaying the HA stem on nanoparticles ((Impagliazzo et al.,
2015); (Yassine et al., 2015)). The HA stem trimers stabilized in
the prefusion conformation induced neutralizing antibodies tar-
geting stems of various group 1 HA subtypes and protected ani-10 Cell Reports 37, 109929, November 2, 2021mals from heterotypic IAV challenge. A
similar strategy basedon structure-guided
vaccine design was successfully applied
to more distantly related group 2 IAVs
((Boyoglu-Barnum et al., 2020); (Corbett
et al., 2019)).
In this study, we extended our struc-
ture-guided design strategy to generate
MERS-CoV-S2-only antigens, with the
intention of eliciting cross-reactive anti-
bodies against conserved S2 epitopes.
Using the PROSS server (Goldenzweig
et al., 2016) to identify candidate stabiliz-
ing mutations and biochemical analyses
to down select expressed S2 mutant pro-teins, we arrived at two S2 subunit constructs optimized for sta-
bility, conformational fidelity, and product yields as immuno-
gens. Intra-protomer disulfide bonds were the most effective
means of enhancing protein expression and thermostability.
The Cys803-Cys933 pair was introduced to cross-link regions
of mobility and immobility during the pre- to post-fusion transi-
tion in a manner similar to the Cys155-Cys290 substitution in
RSV F (DS-Cav1) ((McLellan et al., 2013)). We also aimed to
make a covalent linkage across the S20 protease cleavage site,
by the formation of a Cys838-Cys1089 bridge, akin to the Cy-
s93(HA2)-Cys310(HA1) substitution in the HA stem ((Impagliazzo
et al., 2015)). Finally, Cys898 and Cys1022 substitutions were
placed in the FP and HR1 to prevent the helix-loop region from
transitioning to a single, elongated helix. Both Cys898 and
Cys1022 substitutions were at regions that move substantially,
and a similar approach was used to increase the trimer fraction
of HA stem (Cys68-Cys76) and to keep PIV3 F in a prefusion
conformation (Cys162-Cys168) ((Impagliazzo et al., 2015);
(Stewart-Jones et al., 2018)). Disulfide engineering has also
been used to restrict local flexibility of secondary structures in
SARS-CoV-2 S (Hsieh et al., 2020) or to trap the RBDs in a closed
configuration (Henderson et al., 2020; McCallum et al., 2020;
Figure 7. Passive transfer of IgG22 protects mice from lethal SARS-CoV-2 challenge
(A) BALB/c mice (N = 10/group) were treated with 20mg/kg of mAbG4 (green), 20mg/kg of IgG22 (blue), or 2 mg/kg (light blue) intraperitoneally on the day before
challenge.
(B) Following challenge, mice were monitored for weight loss.The mean of each group is represented by a circle, error bars represent SEM.
(C–E) On day 4 post-challenge, lungs were harvested for analysis of tissue discoloration (C) and viral titers (D). Nasal turbinates were harvested for analysis of viral
titers (E). Each circle represents an individual mouse. Box and whisker plots are shown. Boxes and horizontal bars denote the interquartile range (IQR) and
medians, respectively; whisker end points are equal to the maximum and minimum values. Dotted lines represent lower limit of detection.
In (B), experimental groups were compared to the PBS control group at each day post-challenge by one-way ANOVA with Kruskal-Wallis post test. In (C) to (E),




OPEN ACCESSXiong et al., 2020). Most importantly, MERS SS V2 elicited 10-
fold higher neutralizing antibodies against MERS-CoV than SS
V1 in a single prime-boost immunization regimen. Each disulfide
substitution significantly improved the thermostability of the
MERS SS antigens, consistent with disulfide designs in other
class I viral fusion proteins.
The cavity-filling approach proved to be successful in stabiliz-
ing loosely packed regions of RSV F in its prefusion conformation
((Krarup et al., 2015); (McLellan et al., 2013)). We applied this tac-
tic in the optimization of a stable S2-only MERS immunogen by
substituting Ser975 and Val983 with Met and Ile, respectively,
at the base of MERS-CoV SS. These changes neatly filled a hy-
drophobic pocket between HR1 and amino acids that remain
stationary during the pre- to post-fusion transition. A lone
S975M change proved to be the most effective, leading to
more than a 10-fold increase in protein yields relative to the
parental molecule. Similarly, the N1132Y substitution seems topack against Pro937, Val1206, and Pro1131 and possibly forms
H bonds with Gln800 and Asn1029. Other modifications in-
tended to enhance polar interactions—for instance, V958S,
S1091E, and L1094Q substitutions—were considered as benefi-
cial additions to our best construct. Alternative strategies, such
as stabilizing proline substitutions, reducing hydrophobicity at
the S1-S2 interface, and nanoparticle display, are viable options
to further improve our MERS SS.V2 antigens in efforts to induce
cross-neutralizing antibodies.
MERS SS immunization stimulated the production of anti-
bodies that were cross-reactive to multiple CoV S proteins. To
date, our study is the first to show protection against lethal
MERS-CoV challenge with a stem-only immunogen—protection
that comes without elicitation of potent neutralizing antibody
responses. Previous studies suggest that in vivo activity of
influenza virus stem-specific antibodies rely on Fc-mediated
functions (DiLillo et al., 2014, 2016). In fact, only a handful ofCell Reports 37, 109929, November 2, 2021 11
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OPEN ACCESSS2-specificneutralizing antibodies againstMERS-CoVhavebeen
defined (Wang et al., 2015; Widjaja et al., 2019). One of these an-
tibodies, murine mAb G4, protects against challenge in a murine
lethal model of MERS-CoV infection and binds a hypervariable
loop containing a unique N-glycosylation site in the CD (Pallesen
et al., 2017; (Wang et al., 2018)). Roughly one-third of MERS-SS-
reactive antibodies compete with G4 Fab for the loop epitope,
which suggests at least two types of neutralizing antibodies
(G4-likeandstalk-targeting)wereelicitedbyMERS-stem-onlyan-
tigens. Deletion of the highly immunogenic loop from an S2 sub-
unit vaccinemight beadvantageous topreventnatural immunofo-
cusing on an epitope poorly conserved among even closely
related lineage C b-HCoVs.
Our study also describes a conserved epitope near the base of
S, distinct from the G4-binding site. Two antibodies that recog-
nize this epitope, namely, IgG22 and IgG72, display heterotypic
binding to all highly pathogenic b-HCoVs. Both antibodies
neutralize authentic MERS-CoV and at low nM concentrations
in the case of IgG22. However, IgG72 demonstrated markedly
reduced neutralizing activity against MERS-CoV as compared
to IgG22 (approximately a 10-fold reduction in inhibitory titer).
Cryo-EM structures of Fab22 complexed with MERS S-2P and
prefusion-stabilized SARS-CoV-2 S (HexaPro) revealed the Fab
binding site to be in close proximity to the helical portion of the
stem, a region that is highly conserved within b-CoVs. Although
the binding interface was incompletely resolved in the cryo-EM
maps, we were able to obtain high-resolution crystal structures
of stalk peptide–Fab22 complexes, which revealed a conserved
bindingmodality of the stalk-targeting antibody. The Fab22 bind-
ing site is within a stem helix that must dramatically refold to form
a six-helix bundle with HR1, which leads to virus-cell fusion.
Sequence alignments of Fab22 and Fab72 reveal only four amino
acid differences—one in CDR-L3 and three in CDR-H2—and
none of them directly interact with the stem helix, plausibly ex-
plaining sharedbinding profiles for HCoVSproteins (Figure S6C).
The faster (nearly 100-fold) dissociation rate of Fab22 for
HexaPro (and SARS-CoV S-2P) than that for MERS-CoV S-2P
provides an explanation for the undetectable heterotypic neutral-
izing activity by IgG22 (and IgG72). We note that similar anti-
bodies have been recently described (Pinto et al., 2021; Sauer
et al., 2021; Zhou et al., 2021), including some isolated from
humans.
We explore the potential function of the cross-reactive anti-
body IgG22 by assessing its ability to provide protection in lethal
challenge models of MERS-CoV and SARS-CoV-2. Although
mAb G4 has been shown to induce protection at 20 mg/kg in
mouse models ((Wang et al., 2018)), here, we confirm its speci-
ficity for MERS-CoV and demonstrate that IgG22 at the equiva-
lent dose protects against not only homologous challenge but
also a SARS-CoV-2 lethal challenge. The specificity of mAb G4
toward a highly variable glycosylated loop in the generally well-
conserved S2 domain of MERS-CoV (Pallesen et al., 2017) may
help explain its failure to both cross-react and to protect against
SARS-CoV-2 challenge. Our studies reveal that unlike G4, IgG22
recognizes a highly conserved site in S2 that drives virus-cell
fusion, which provides a rationale for why targeting this site pro-
tects against other b-CoVs. Although our studies demonstrated
that IgG22 fails to neutralize authentic SARS-CoV-2, it signifi-12 Cell Reports 37, 109929, November 2, 2021cantly reduced tissue damage and lung discoloration scores
compared to untreatedmice and promoted rapid clearance of vi-
rus from the lower respiratory tract. Passive administration of
IgG22 did not reduce virus replication in the upper respiratory
tract, corroborating recent findings that the threshold for IgG-
mediated inhibition of SARS-CoV-2 replication is lower for the
lung than upper airways (Corbett et al., 2021). These findings
emphasize the importance of determining other functionalmech-
anisms by which non-neutralizing antibodies protect, especially
in the context of cross-protection. Identifying the conserved
IgG22 binding site may inform future vaccine designs needed
not only to manage the ongoing pandemic but also for the devel-
opment of broader vaccines to combat future spillovers of novel
CoVs into humans. Identification of sites, like IgG22’s binding
epitope that cannot freely accumulate substitutions to avoid
loss-of-functionmutations, enables vaccine development efforts
to target sites less likely to escapeantibody-mediatedprotection.
As current vaccines use full-length SARS-CoV-2 S antigens, the
immunodominant RBD and NTD skew humoral responses upon
immunization—which may have reduced activity against SARS-
CoV-2 VOCs harboring conformational changes in the S1
domain. The use of stem antigens may lessen the selective pres-
sure for advantageous substitutions in the regions that are
responsible for interacting directly with host cells.
In summary, this study provides a proof of concept that the
CoV S stem can be rationally engineered as a stabilized immu-
nogen to elicit antibodies cross-reactive with all three epidemic
b-HCoVs and to provide complete protection in animals against
a lethal MERS-CoV challenge. Using a SS construct, we induced
the production of antibodies that enabled the identification of
a site of vulnerability in the S2 subunit, which will inform the
development of next-generation CoV vaccines and fortify CoV
pandemic preparedness.
Limitations of the study
One limitationof this study is the lackof structuraldatashowing the
extent towhich the stabilizingmutations in theMERS-CoVS2sub-
unit favor the prefusion conformation. Further structure-based de-
signs focused on stabilizing the trimer interface could potentially
lead tomore native-like S2 immunogens. In addition, optimization
of the helical stalk regions where the cross-protective antibodies
boundcould beanalternative approach todesignnext-generation
pan-CoV vaccines. Another limitation is that the immunogen did
not provide cross-protection for animals against SARS-CoV-2
infection. Elicitation of broadly neutralizing or protective sera is
desirable, but these first-generation immunogens were unable to
meet that standard. Although IgG22 provided protection in mice
against both MERS-CoV and SARS-CoV-2 challenge, additional
immunogenicity studies conducted in non-human primates need
to be performed to strengthen this conclusion.
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PierceTM Protein A Agarose ThermoFisher Scientific Cat# 20334
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Biacore X100 Sensorchip NTA GE Healthcare Cat# BR100407
Superose 6 increase 10/300 GL GE Healthcare Cat# 29091596
Sigma Adjuvant System Sigma-Aldrich Cat# S6322-1VL
Carbon Film 400 Mesh, Cu Electron Microscopy Sciences Cat# CF400-Cu-50
C-Flat Holey Carbon Grid CF-1.2/1.3-4C,
400 mesh Cu





Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jason
McLellan (jmclellan@austin.utexas.edu).
Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
Data and code availability
d Atomic coordinates for the Fab22–MERS-CoV S peptide and the Fab22–SARS-CoV-2 S peptide structures have been depos-
ited into the Protein Data Bank and assigned PDB IDs 7S3M and 7S3N, respectively. Cryo-EM maps of Fab22–MERS-CoV S-
2P and Fab22–SARS-CoV-2 S-HexaPro have been deposited in the EMDB and assigned codes EMD-25072 and EMD-25073.
d This paper does not report original code.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
FreeStyle293F mammalian cells (ThermoFisher) were maintained in FreeStyle293 expression medium (ThermoFisher) in a 37C
shaker supplied with 8% CO2 and 80% humidity. Huh7.5, Vero81, and Vero E6 cells were incubated in DMEM (ThermoFisher) at
37C and 5% CO2.
Mouse strains
Female BALB/cJmice andC57BL/6Jmice aged 6- to 8-weekswere obtained from Jackson Laboratory. Female 10-week-old BALB/c
wereobtained fromEnvigo (BALB/cAnNHsD; stock # 047). Sixteen to 20-week-oldmale and female 288/330+/+micewere generated in
the Baric Laboratory. All mouse experiments were carried out in compliance with all pertinent US National Institutes of Health regula-
tions and approval from the Animal Care and Use Committee (ACUC) of the Vaccine Research Center, from Institutional Animal Care
and Use Committee at University of North Carolina at Chapel Hill to guidelines outlined by the Association for the Assessment and
Accreditation of Laboratory Animal Care and the U.S. Department of Agriculture, or fromACUC of Abcellera Biologics. All infection ex-
periments were done in animal biosafety level 3 (BSL-3) facilities at the University of North Carolina at Chapel Hill.
METHOD DETAILS
Design scheme for MERS SS variants
The base construct used for the S2 subunit of MERS-CoV S-2P variant contained residues 762-1291 of MERS-CoV S (GenBank ID:
AFY13307) with proline substituted at residues 1060 and 1061, the foldon trimerization motif of T4 fibritin, an HRV3C protease recog-
nition site, an octa-histidine tag, and a tandem Twin-Strep-tag, cloned into the mammalian expression plasmid paH. All mutations in
subsequent designs were introduced into this base construct. The initial design was conducted via the PROSS server (Goldenzweig
et al., 2016), and a total of 11 substitutions were picked (yielding the ‘mut11’ construct) from 53 computational designs based on the
biochemical property of the residues and steric effect on the prefusion-stabilized MERS S-2P structure (PDB ID: 5W9I). Using struc-
ture-based design, additional substitutions that were aimed at favoring the stability of the prefusion structure were introduced into the
mut11 backbone. Pairs of core-facing residues less than 5 Å apart were replaced with aromatic sidechains or pairs of aromatic and
positively charged sidechains to favor pi-pi or pi-cation interactions, respectively. Alternatively, residueswere replacedwith extendede3 Cell Reports 37, 109929, November 2, 2021
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bility or prevent formation of the postfusion conformation. The charged or polar substitutionswere aimed to establish hydrogen bonds
or salt bridges with the native residues that were predicted to be within 4.0 Å. To examine the effect of the substitutions in the mut11
backbone, themutationswere individually or combinatorially revertedback to thewild-type sequence. Threedesigns, eachcontaining
5–7of thebeneficial substitutions from thePROSSserver (mut5,mut6andmut7)werechosen to serveasbackgrounds for subsequent
rounds of design. These were then combined with individual substitutions or combinations of substitutions from the structure-based
designs that were shown to be beneficial, for subsequent assessment of improvedmonodispersity and thermostability. Substitutions
predicted to potentially interfere with one another or clash with native residues were avoided.
Expression and purification of MERS SS
Plasmids encoding MERS SS variants were transiently transfected into FreeStyle293F cells (Thermo Fisher) using polyethylenimine,
with 5 mM kifunensine being added 3h post-transfection. Cultures were grown for 6 days, and culture supernatant was separated via
centrifugation and passage through a 0.22 mm filter. Protein was purified from supernatants using StrepTactin resin (IBA). MERS SS
variants were further purified by size-exclusion chromatography (SEC) using a Superose 6 increase 10/300 column (GEHealthcare) in
a buffer composed of 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3. For initial purification and characterization, single-substi-
tution and combinatorial variants were purified from 40 mL cultures. The SS.V1 and SS.V2 variants were further tested in large-scale
expression and purification from 1 L cultures. The protein purity, monodispersity and expression level were determined by SDS-
PAGE and SEC.
Differential scanning fluorimetry
MERS SS variants were prepared at a concentration of 1.5 mMwith a final concentration 5X SYPRO Orange Protein Gel Stain (Ther-
moFisher) in a white, opaque 96-wellplate. Continuous fluorescence measurements (lex = 465 nm, lem = 580 nm) were performed
using a Roche LightCycler 480 II, with a temperature ramp rate of 4.4C/minute, and a temperature range of 25C to 95C. Data were
plotted as the derivative of the melting curve.
Mouse Experiments
All mouse experiments were carried out in compliance with all pertinent US National Institutes of Health regulations and approval
from the Animal Care andUseCommittee (ACUC) of the Vaccine Research Center, from Institutional Animal Care andUseCommittee
at University of North Carolina at Chapel Hill to guidelines outlined by the Association for the Assessment and Accreditation of Lab-
oratory Animal Care and the U.S. Department of Agriculture, or from ACUC of Abcellera Biologics. All infection experiments were
done in animal biosafety level 3 (BSL-3) facilities at the University of North Carolina at Chapel Hill. For immunogenicity studies, female
BALB/cJ mice aged 6- to 8-weeks (Jackson Laboratory) were used. Per the experimental design schema outlined in Figure 3A, mice
were inoculated intramuscularly with protein immunogens adjuvanted with SAS as previously described (Pallesen et al., 2017) and
bled for serological assays. For challenge studies to evaluate MERS-CoV vaccines, 16- to 20-week-old male and female 288/330+/+
mice (Cockrell et al., 2016) were immunized, bled, and challenged, as detailed in Figure 4A.Mice were challenged with 53 105 PFU of
a mouse-adapted MERS-CoV EMC derivative, maM35c4 (Douglas et al., 2018). On days 3 and 5 post-challenge, lungs were
collected from selected mice to assess viral titers and discoloration, using previously published methods. Briefly, caudal right
lung lobes were harvested for analysis of viral load by plaque assay. Lung lobes were homogenized in 1mL of PBS and glass beads.
Clarified homogenates were used to inoculate monolayers of Vero E6 cells for SARS-CoV-2 MA10 or Vero CCL81 cells for MERS-
CoV maM35c4 which were stained with Neutral Red dye after 72 hours to visualize plaques. For S-reactive monoclonal antibody
isolation, female C57BL/6J mice aged 4- to 8-weeks (Jackson Laboratory) were used. Mice were immunized intramuscularly with
10 mg MERS SS.V1 + SAS at weeks 0, 3, and 9. At week 13, mice were euthanized and spleens, thymuses, and lymph nodes
were harvested for single B cell technology for mAb isolation. For passive transfer studies to consider the protective efficacy of
IgG22 in MERS- and SARS-CoV-2 challenges, male and female 288/330+/+ mice aged 16–20 weeks (Cockrell et al., 2016) and
10-week-old female BALB/cmice (Dinnon et al., 2020) (Envigo), respectively, received either 20mg/kg or 2mg/kg of antibody diluted
appropriately in 1X PBS via intraperitoneal injection one day prior to challenge. On the day of challenge, mice were infected intrana-
sally with 53 105 PFUMERS-CoVmaM35c4, or 1 x 104 PFUSARS-CoV-2MA10 (Leist et al., 2020). For 288/330+/+mice infectedwith
MERS-CoV, mice were monitored up to 5 days post-challenge, and were euthanized and lungs were collected to investigate lung
discoloration, viral burden, and nasal turbinate was collected from select mice to determine viral burden in the upper airway as
described above. For BALB/c mice infected with SARS-CoV-2, mice were monitored up to 4 days post-challenge, and were eutha-
nized and lungs were collected to investigate lung discoloration, viral burden, and nasal turbinate was collected from select mice to
determine viral burden in the upper airway as described above. Sample size for animal experiments was determined on the basis of
criteria set by institutional ACUC. Experiments were neither randomized nor blinded.
Serum IgG Measurement
HCoV S-2P-specific IgG in immunized mouse sera were quantified via enzyme-linked immunosorbent assay (ELISA). Briefly, Nunc
MaxiSorp 96-well plates (ThermoFisher) were coated with either MERS S-2P, SARS S-2P, SARS-CoV-2 S-2P, or HKU1 S-2P at 1 mg/
mL in 1X PBS at 4C for 16h. Sera dilutions were prepared in blocking buffer, which consisted of PBS-Tween 20 + 5% non-fat dairyCell Reports 37, 109929, November 2, 2021 e4
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and incubated for an hour at room temperature. After standard washes and blocks, goat anti-mouse IgG-horseradish peroxidase
(HRP) conjugate (SigmaAldrich) was used as secondary antibody. Plates were reacted with 3,5,305’-tetramethylbenzidine (TMB)
(KPL) to detect binding responses. Plates were read at OD450/650 using SpectraMax Paradigm (Molecular Devices). Endpoint titers
were calculated as the reciprocal serum dilution that yielded a signal 4x greater than that of the background signal (secondary anti-
body alone).
MERS-CoV Pseudovirus Neutralization Assay
Neutralization activity was assessed as previously described (Pallesen et al., 2017). Briefly, Huh7.5 cells were seeded at 10,000 cells/
well in 96-well black/white Isoplates (PerkinElmer) 24-h prior to infection. Sera were serially diluted (1:40, 4-fold dilutions, 8x) in
DMEM (GIBCO) + 1% penicillin/streptomycin, and mixed with a pseudotyped MERS-CoV England1 lentivirus reporter that was pre-
viously titrated to 104 RLU, and incubated for 30 minutes at room temperature. The sera + pseudovirus mixture was then added to
Huh7.5 cells in duplicate, and incubated at 37C and 5% CO2 for 2h. Then, 100 mL of DMEM supplemented with 10% FBS, 2 mM
glutamine, and 1% penicillin/streptomycin was added to each well, and incubated for 72h. Cells were then lysed, and luciferase sub-
strate (Promega) was added. Luciferase activity was measured as relative luciferase units (RLU) at 570 nm, using a SpectraMaxL
(Molecular Devices). Sigmoidal curves, taking averages of triplicates at each dilution, were generated from RLU readings; 50%
neutralization (ID50) titers were calculated considering uninfected cells as 100% neutralization and cells transduced with only virus
as 0% neutralization, by fitting RLU readings to a log(agonist) versus normalized-response (variable slope) nonlinear regression
model in Prism v9 (GraphPad).
Single-cell screening and recovery
Immunized mice exhibiting elevated serum titers were sacrificed and plasma cells from lymph node, spleen, and bone marrow tis-
sues were isolated using standard protocols. Samples were screened with AbCellera’s high-throughput single-cell microfluidic plat-
form using amultiplexedmicrobead assay on devices containing individual nanoliter-volume reaction chambers (Lecault et al., 2011).
The multiplexed assay employed multiple optically-encoded beads, each conjugated to one of the following unique antigens: full-
length pre-fusion stabilized S proteins of MERS-CoV, SARS-CoV, or HKU1-CoV, or the S2 subunit of MERS-CoV S. Bead-conju-
gated bovine serum albumin (BSA) His-tag and T4 foldon trimerization domain were used as negative controls. Beads were flowed
into microfluidic screening devices and incubated with single antibody-secreting cells, and monoclonal antibody binding to cognate
antigens was detected via a fluorescently labeled anti-human IgG secondary antibody. Positive hits were identified using machine
vision and recovered using automated robotics-based protocols.
Single-cell sequencing and cloning
For recovery of paired heavy and light chain sequences, single-cell polymerase chain reaction (PCR) and next-generation sequencing
(MiSeq, Illumina) were performed using automated workstations (Bravo, Agilent) and custom molecular biology protocols. Se-
quences were analyzed using a custom bioinformatics pipeline to yield paired heavy and light chain sequences for each recovered
antibody-secreting cell. Each sequence was assigned the closest germline (V(D)J) genes, degree of somatic hypermutation, and po-
tential sequence liabilities.
Expression and purification of antibodies
Twenty monoclonal antibodies discovered by single B cell technology were selected for characterization based on their binding
specifies to HKU1-S, MERS-S and SARS-1-S (monospecific, bi-specific or tri-specific), diversity of heavy and light chain CDR3s,
and high frequency rates in the B cell repertoire (independently isolated by the probesmore than 2 times). The individual VH sequence
of selected IgGs was cloned into a mammalian expression plasmid pVRC8400 containing HRV 3C cleavage site in the hinge, and
human IgG1 Fc domain. VL sequences were also cloned into pVRC8400 with human CL. Paired VH and VL in a 1:1 ratio were co-
transfected transiently into FreeStyle293F cells as previously described. The supernatant was harvested six days post-transfection
and IgGs were purified with Protein A agarose (ThermoFisher). IgGs were eluted with 100 mM glycine, pH 3 into 1/10th volume 1 M
Tris-HCl pH 8.0. IgGswere then buffer exchanged into PBS pH 7.4. Fabswere generated by digesting the IgGswith HRV 3C protease
at 4C. Fc was removed by passing digests over fresh Protein A agarose, leaving the Fab in the flowthrough, which was further pu-
rified by SEC using a Superdex 200 increase 10/300 column (GE Healthcare) in PBS buffer, pH 7.4.
Biolayer interferometry
The binding affinity of purified IgGs to HKU1-CoV S, MERS-CoV S or SARS-CoV S was characterized by BLI using an Octet RED96e
(FortéBio). Briefly, anti-human Fc (AHC) sensors (FortéBio) with captured IgG were dipped into the wells containing 100 nM of CoV S
in a BLI buffer composed of 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% v/v Tween 20 and 1 mg/ml BSA. After 600 s association
step, the dissociation step was carried out in the wells containing only BLI buffer for 600 s. RSV F-foldon was also included in the
experiments as negative control. The binding affinity of purified mAb G4 to MERS-CoV S and MERS SS was also characterized
by BLI using a similar approach. AHC sensors with captured mAb G4 were dipped into the wells containing serial dilutions of
MERS-CoV S or MERS SS at concentrations ranging from 100 to 1.56 nM in a BLI buffer. The data were aligned to a baseline priore5 Cell Reports 37, 109929, November 2, 2021
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v11.1. The IgGs exhibiting binding to MERS-CoV S were further examined for the ability to compete with mAb G4, the only S2-tar-
geted MERS-S antibody with a defined epitope (Pallesen et al., 2017). Four-fold molar excess of G4 Fab was preincubated with
100 nM MERS-S at room temperature for 10 min. The IgG being tested was loaded on AHC sensors and then dipped into either
100 nM apo MERS-S or 100 nM G4-presaturated MERS-S. G4 IgG was also included in one set of the experiments as a control.
The data were plotted as the difference between the binding level of G4-saturated and apo MERS-S, normalized to the binding level
of apo MERS-S to the IgG of interest.
Surface Plasmon Resonance
To accurately determine the binding kinetics, His-tagged S variants (MERS-CoV S-2P, SARS-CoV S-2P and SARS-CoV-2 S-Hex-
aPro) were immobilized to a Ni-NTA sensorchip (GE Healthcare) to a level of 600 response units (RUs) using a Biacore X100 (GE
Healthcare) and running buffer composed of 10 mM HEPES pH 8.0, 150 mM NaCl and 0.05% Tween 20. Serial dilutions of purified
Fab22 were injected at concentrations ranging from 400 to 6.25 nM over immobilized MERS-CoV S-2P. For the SARS-CoV S-2P and
SARS-CoV-2 S-HexaPro binding experiments, Fab22 concentrations ranging from 100 to 3.13 nM were used instead. The Ni-NTA
sensorchip was regenerated between each cycle with 0.35 M EDTA, 50 mM NaOH and followed by 0.5 mM NiCl2. Response curves
were double-reference subtracted and fit to a 1:1 binding model using Biacore X100 Evaluation Software (GE Healthcare).
Plaque-reduction neutralization test (PRNT)
Four-fold serial dilutions of mAbs were combined with an average of 124 plaque-forming units of MERS-CoV (HCoV-EMC/2012) or
SARS-CoV-2 (SARS-CoV-2/human/USA/USA-WA1/2020) in 200 mL gelatin saline (0.3% [wt/vol] gelatin in phosphate-buffered saline
supplemented with CaCl2 and MgCl2) for 20 min at 37
C, and 100 mL of virus-mAbmixture was applied to each of two confluent Vero
81 or Vero E6 cell monolayers, respectively, in 6-well (10-cm2) plates. Monolayers were overlaid with Dulbecco’s modified Eagle’s
medium (DMEM) containing 1% agar following virus adsorption for 30 min at 37C, and plaques were enumerated at 72 h or 96 h
post-infection. Percent plaque reduction resulting from mAb treatment (relative to untreated virus control) was plotted as a function
of log10 mAb concentration. Neutralization data were subjected to five-parameter logistic regression modeling using PRISM 9
(GraphPad). Minimum mAb concentrations resulting in 50% and 80% virus neutralization were interpolated from fitted dose-
response curves.
Negative stain EM for S-Fab complexes
Purified MERS-CoV S-2P or SARS-CoV-2 S-HexaPro were incubated with 2-fold molar excess of Fab22 or Fab72 or Fab20 in 2 mM
Tris pH 8.0, 200 mMNaCl and 0.02%NaN3 at room temperature for 30 min. The S-Fab complexes were diluted to a concentration of
0.06mg/mL in 2mMTris pH 8.0, 200mMNaCl and 0.02%NaN3. Each protein complex was deposited on aCF-400-CUgrid (Electron
Microscopy Sciences) that had been plasma cleaned for 30 s in a Solarus 950 plasma cleaner (Gatan) with a 4:1 ratio of O2/H2 and
stained using methylamine tungstate (Nanoprobes). Grids were imaged at a magnification of 92,000X (corresponding to a calibrated
pixel size of 1.63 Å/pix) in a Talos F200C TEM microscope equipped with a Ceta 16M detector (Thermo Fisher Scientific). The CTF-
estimation and particle picking were performed in cisTEM (Grant et al., 2018). Particles were then imported into cryoSPARC v2.15.0
for 2D classification (Punjani et al., 2017).
Cryo-EM
PurifiedMERS-CoV S-2P at 1mg/mLwas incubated with 2-foldmolar excess of Fab22 in 2mMTris pH 8.0, 200mMNaCl and 0.02%
NaN3 at room temperature for 30 min. Sample was then deposited on a plasma-cleaned CF-400 1.2/1.3 grid before being blotted for
5 swith +1 force in a VitrobotMark IV (ThermoFisher) and plunge-frozen into liquid ethane. Similarly, purified SARS-CoV-2 S (HexaPro
variant) complexed with 2-fold molar excess of Fab22 was diluted to a concentration of 0.37 mg/mL in 2 mM Tris pH 8.0, 200 mM
NaCl, 0.02%NaN3 and applied to plasma-cleaned CF-400 1.2/1.3 grids before being blotted for 3.5 s with4 force in a Vitrobot Mark
IV and plunge-frozen into liquid ethane. For the Fab22-MERS S-2P sample, 4330 micrographs were collected from a single grid. For
the Fab22-HexaPro sample, 2,013 micrographs were collected from a single grid. FEI Titan Krios (ThermoFisher) equipped with a K3
direct electron detector (Gatan) was used for imaging. Data were collected at a magnification of 22,500x, corresponding to a cali-
brated pixel size of 1.07 Å/pix. A full description of the data collection parameters can be found in Table S1.Warpwas used formotion
correction, CTF estimation, and particle picking ((Tegunov and Cramer, 2019)). The particle stackwas then imported into cryoSPARC
v2.15.0, which was used to curate the particles via iterative rounds of 2D classification (Punjani et al., 2017). The final reconstructions
were then arrived at via ab initio reconstruction, heterogeneous refinement, and subsequently non-uniform homogeneous refinement
of final classes. The structure validation can be found in Figure S5.
X-ray crystallography
To crystallize the Fab22–MERS-stem-helix-peptide complex, MERS stem helix peptide (DFQDELDEFFKNVST, GenScript) was
added in 4-fold molar excess to Fab22, resulting in a final concentration of 14 mg/ml Fab22 and 2 mg/ml peptide in 2 mM Tris pH
8, 200 mM NaCl, 0.02% NaN3. Peptide complex (0.1 ml) was mixed with 0.1 mL mother liquor (10% PEG1000, 10% PEG8000) using
anNT8 (Formulatrix), and the 0.2 mL dropwas spotted onto anMRC2 crystallization tray to allow for vapor diffusion, with 60 mLmotherCell Reports 37, 109929, November 2, 2021 e6
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chain constant Ig domain (CL) that favors Fab crystallization was used (LCmod-Fab22, HQGLSSP to QGTTS) (Lieu et al., 2020).
SARS-CoV-2 stem helix peptide (DSFKEELDKYFKNHTSPDVD, GenScript) was added in 5-fold molar excess to LCmod-Fab22, re-
sulting in a final concentration of 11 mg/ml LCmod-Fab22 and 2.1 mg/ml peptide in 2 mM Tris pH 8, 200 mM NaCl, 0.02% NaN3.
Peptide complex (0.1 ml) was mixed with 0.05 mL mother liquor (0.1 M sodium citrate pH 5.5, 23% PEG8000) using an NT8 (Formula-
trix), and the 0.15 mL drop was spotted onto an MRC2 crystallization tray to allow for vapor diffusion, with 60 mL mother liquor in the
well. Crystals were rapidly soaked in their respective mother liquors supplemented with 30% ethylene glycol, looped, and flash-
frozen in liquid nitrogen. Remote data collection was performed at the SBC beamline 19ID (Advanced Photon Source, Argonne Na-
tional Laboratory). Diffraction data were indexed and integrated in iMOSFLM (Battye et al., 2011), before beingmerged and scaled (to
2.4 Å for MERS peptide complex and to 1.9 Å for SARS-CoV-2 peptide complex) using Aimless (Evans and Murshudov, 2013). Mo-
lecular replacement was performed in Phaser (McCoy et al., 2007), and models were then subjected to multiple rounds of model
building and refining in Coot and Phenix, respectively (Adams et al., 2002; Emsley and Cowtan, 2004). Data collection and refinement
statistics can be found in Table S2.
QUANTIFICATION AND STATISTICAL ANALYSIS
Figure legends detail all quantification and statistical analyses, inclusive of animal numbers (n), dispersion and precision measures,
and statistical tests. For comparisons of antibody responses and challenge outcomes between experimental groups, one-way
ANOVA with Kruskal-Wallis post-tests were used. Serum IgG endpoint titers and pseudovirus neutralizing antibody titers were trans-
formed so that all values were on a log(10) scale prior to statistical analyses. All one-way ANOVA analyses did not assume Gaussian
distribution and were performed as non-parametric tests. One-way ANOVA analyses with Kruskal-Wallis post-tests corrected for
multiple comparisons using statistical hypothesis testing via Dunn’s tests. For comparisons of serum IgG endpoint titers (Figures
2B–2E), two-way ANOVA analyses were performed between groups receiving the same dose of different immunogens, and between
groups receiving the same immunogen at different doses. Two-way ANOVA analyses with multiple comparisons compared values
within each row across columns; i.e., each cell mean was compared with every other cell mean within their respective row. Correc-
tions for multiple comparisons using statistical hypothesis testing were performed via Sidak tests for all two-way ANOVA analyses.
p values are summarized within figures as: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001. All statistical analyses were conducted using
Graphpad Prism v9.0.2, i.e., geometric mean titers (GMT), means, and SEM (standard error of the mean) for serum IgG endpoint ti-
ters, pseudovirus neutralization titers, plaque reduction neutralization titers, body weight loss of mice in challenge assessments,
mouse lung viral loads, and discoloration scores.e7 Cell Reports 37, 109929, November 2, 2021
